A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 15, 2018

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Stress Disorders, Post-Traumatic
Interventions
DRUG

Doxazosin Mesylate, Extended Release

Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).

DRUG

Placebo

Placebo, or inactive pill.

Trial Locations (1)

94121

San Francisco VA Medical Center, San Francisco

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Northern California Institute of Research and Education

OTHER

lead

San Francisco Veterans Affairs Medical Center

FED

NCT03339258 - A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD | Biotech Hunter | Biotech Hunter